Exelixis Files IND Application for Novel Anticancer Compound XL820

Exelixis has submitted an investigational new drug application (IND) to the FDA for XL820.

This novel small molecule anticancer compound potently inhibits receptor tyrosine kinases implicated in tumor proliferation and vascularization. XL820 is the fifth compound to advance in clinical development from Exelixis' internal drug discovery capabilities.

Pending clearance by the FDA, Exelixis intends to initiate a Phase I clinical trial for XL820.